NDA 011145 · Rising
Diuril
Chlorothiazide, Chlorothiazide Sodium · Oral, Injection
NovelPriority reviewDiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 20, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1958
Sep 4, 1958
Approved uses
1
Original approval plus efficacy supplements
Registered trials
330
91 Phase 3, 10 recruiting
FAERS reports
1,263
1,011 serious, 199 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 4, 1958 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- DIURIL · CHLOROTHIAZIDE 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- DIURIL · CHLOROTHIAZIDE 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- DIURIL · CHLOROTHIAZIDE SODIUM EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorothiazide" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Diuretic Comparison ProjectPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02185417 · 20,723 participants · Start Jun 15, 2016 · Primary completion Oct 15, 2022
Drug: Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD) · For: Hypertension
Sites: Birmingham, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 70 sites in all
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
- Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00263393 · 3,712 participants · Start Dec 2005 · Primary completion Dec 2008
Drug: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin · For: Myocardial Infarction; Angina Pectoris; Cerebrovascular Accidents and 1 more
Sites: Bhimavaram, India
- Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan AlonePivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00170989 · 2,714 participants · Start Sep 2004 · Primary completion Jul 2005
Drug: valsartan plus hydrochlorothiazide · For: Hypertension
Sites: Investigative Centers, Germany; Basel, Switzerland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use88
- dyspnoea81
- pyrexia79
- diarrhoea73
- hypotension71
- drug ineffective66
- pneumonia63
- respiratory failure62
- pain59
- vomiting52
- death50
- cough48
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 25 |
| 2006 | 19 |
| 2007 | 25 |
| 2008 | 16 |
| 2009 | 27 |
| 2010 | 35 |
| 2011 | 55 |
| 2012 | 40 |
| 2013 | 53 |
| 2014 | 56 |
| 2015 | 55 |
| 2016 | 84 |
| 2017 | 63 |
| 2018 | 120 |
| 2019 | 107 |
| 2020 | 108 |
| 2021 | 92 |
| 2022 | 93 |
| 2023 | 61 |
| 2024 | 43 |
| 2025 | 41 |
| 2026 | 26 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Diuril (Chlorothiazide)
2024 spending
$21K
Beneficiaries
85
236 claims
Per beneficiary
$247
$0.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,134 |
| 2021 | $24,603 |
| 2022 | $30,867 |
| 2023 | $17,639 |
| 2024 | $20,999 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diuretics use in the management of bronchopulmonary dysplasia in preterm infants: A systematic review.
Ó Briain E, Byrne AO, Dowling J, et al. · Acta Paediatr 2024 · Systematic Review
- Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.
Cox ZL, Hung R, Lenihan DJ, et al. · JACC Heart Fail 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure.
Steuber TD, Janzen KM, Howard ML · Pharmacotherapy 2020 · Meta-Analysis, Systematic Review
- beta-Adrenoreceptor-blocking agents and lipid metabolism.
England JD, Hua AS, Shaw J · Clin Sci Mol Med Suppl 1978 · Clinical Trial, Randomized Controlled Trial
- Hypertension treated by sodium restriction.
Morgan TO, Myers JB · Med J Aust 1981 · Clinical Trial, Comparative Study
- Effects of chlorothiazide on urinary excretion of calcium in clinically normal dogs.
Lulich JP, Osborne CA · Am J Vet Res 1992 · Clinical Trial, Randomized Controlled Trial
Sponsor: Rising
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.